ChengDa Pharmaceuticals Dividend
Dividend criteriumcontroles 2/6
ChengDa Pharmaceuticals is a dividend paying company with a current yield of 0.95% that is well covered by earnings.
Belangrijke informatie
0.9%
Dividendrendement
-0.01%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | 0.9% |
| Toekomstig dividendrendement | n/a |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | CN¥0.200 |
| Uitbetalingsratio | 44% |
Recente dividendupdates
Recent updates
ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) 42% Price Boost Is Out Of Tune With Earnings
Oct 08
There's Reason For Concern Over ChengDa Pharmaceuticals Co., Ltd.'s (SZSE:301201) Massive 42% Price Jump
Oct 08ChengDa Pharmaceuticals (SZSE:301201) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Sep 03ChengDa Pharmaceuticals (SZSE:301201) Will Pay A Smaller Dividend Than Last Year
Jul 05Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: 301201 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Groeiend dividend: 301201 has only been paying a dividend for 3 years, and since then payments have fallen.
Dividendrendement versus markt
| ChengDa Pharmaceuticals Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (301201) | 0.9% |
| Markt onderkant 25% (CN) | 0.6% |
| Markt Top 25% (CN) | 2.2% |
| Gemiddelde industrie (Pharmaceuticals) | 1.7% |
| Analist prognose (301201) (tot 3 jaar) | n/a |
Opmerkelijk dividend: 301201's dividend (0.95%) is higher than the bottom 25% of dividend payers in the CN market (0.57%).
Hoog dividend: 301201's dividend (0.95%) is low compared to the top 25% of dividend payers in the CN market (2.22%).
Winstuitkering aan aandeelhouders
Verdiendekking: With its reasonably low payout ratio (43.5%), 301201's dividend payments are well covered by earnings.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: 301201 is paying a dividend but the company has no free cash flows.